These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 10537366)
1. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Gabrilovich DI; Ishida T; Nadaf S; Ohm JE; Carbone DP Clin Cancer Res; 1999 Oct; 5(10):2963-70. PubMed ID: 10537366 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591 [TBL] [Abstract][Full Text] [Related]
3. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. Ishida T; Oyama T; Carbone DP; Gabrilovich DI J Immunol; 1998 Nov; 161(9):4842-51. PubMed ID: 9794417 [TBL] [Abstract][Full Text] [Related]
4. [Anti-tumor immune response of dendritic cells transfected with wild-type p53 gene]. Liu HJ; Xin JB; Li ZY; Xiong XZ; Tao XN; Hu Y Zhonghua Jie He He Hu Xi Za Zhi; 2008 Dec; 31(12):902-7. PubMed ID: 19134406 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902 [TBL] [Abstract][Full Text] [Related]
8. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. Ohm JE; Shurin MR; Esche C; Lotze MT; Carbone DP; Gabrilovich DI J Immunol; 1999 Sep; 163(6):3260-8. PubMed ID: 10477595 [TBL] [Abstract][Full Text] [Related]
9. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Wood JM Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930 [TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Luo JC; Toyoda M; Shibuya M Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584 [TBL] [Abstract][Full Text] [Related]
12. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082 [TBL] [Abstract][Full Text] [Related]
13. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Borgström P; Gold DP; Hillan KJ; Ferrara N Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376 [TBL] [Abstract][Full Text] [Related]
14. A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. Yoneyama S; Okaji Y; Tsuno NH; Kawai K; Yamashita H; Tsuchiya T; Yamada J; Sunami E; Osada T; Kitayama J; Takahashi K; Nagawa H Eur J Surg Oncol; 2007 Dec; 33(10):1191-8. PubMed ID: 17314028 [TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340 [TBL] [Abstract][Full Text] [Related]
16. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. Melnyk O; Zimmerman M; Kim KJ; Shuman M J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734 [TBL] [Abstract][Full Text] [Related]
17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
18. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma. Dagnaes-Hansen F; Rasmussen LM; Tilton R; Denner L; Flyvbjerg A Anticancer Res; 2003; 23(2B):1625-30. PubMed ID: 12820432 [TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905 [TBL] [Abstract][Full Text] [Related]
20. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]. Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]